Overall, we expect our Drug-ID/isASO-ID protocols to work for other classes of ON drugs, too 1,8 , including splice-switching ASOs, siRNAs, antimiRs and ADAR-recruiting ASOs 51
Discussion of costs and insurance coverage is important given that BPC-157, as an unapproved drug, typically is not covered by health insurance
A systematic review examining studies on BPC-157 and musculoskeletal healing found that the vast majority were preclinical (primarily conducted in rats), with very limited clinical data in humans
Monitor Health Conditions: Regular check-ups help track improvement in nerve function and vitamin levels
WBCIL White Paper on Liposomal Glutathione, 2025
Conservative starting doses would be essential: Initial phase : Cagrilintide 0.3 mg + Tirzepatide 2.5 mg weekly Escalation : Increase cagrilintide by 0.3-0.6 mg every 4 weeks Tirzepatide adjustment : Maintain or modestly increase based on tolerance Monitoring : Close observation for cumulative GI effects This remains speculative, as no published trials have examined this specific combination
